

I. AMENDMENT

IN THE SPECIFICATION

Please amend the specification by entering the attached Sequence Listing.

Please replace the paragraph beginning at page 5, line 22, with the following rewritten paragraph:

- - Figs. 1A and 1B show, respectively, an amino acid sequence of an intact C2B8 heavy chain (SEQ ID NO: 1) and an amino acid sequence of a derived domain deleted C2B8 construct (SEQ ID NO: 2) wherein the C_H2 domain has been deleted; - -

Please replace the paragraph beginning at page 5, line 25, with the following rewritten paragraph:

- - Figs. 2A and 2B show, respectively, a nucleotide sequence of an intact C2B8 heavy chain (SEQ ID NO: 3) and a nucleotide sequence of a derived domain deleted C2B8 construct (SEQ ID NO: 4) wherein the C_H2 domain has been deleted; - -

Please replace the paragraph beginning at page 5, line 28, with the following rewritten paragraph:

- - Figs. 3A and 3B show, respectively, a nucleotide sequence of a C2B8 light chain (SEQ ID NO: 5) and the corresponding amino acid sequence (SEQ ID NO: 6) of the same light chain; - -

Please replace the paragraph beginning at page 6, line 1, with the following rewritten paragraph:

-- Figs. 4A and 4B show, respectively, the amino acid sequence of a huCC49 domain deleted heavy chain (SEQ ID NO: 7) wherein the C_H2 domain has been deleted and a corresponding nucleotide sequence (SEQ ID NO: 8) for the same heavy chain; --

Please replace the paragraph beginning at page 6, line 4, with the following rewritten paragraph:

-- Figs. 5A and 5B show, respectively, an amino acid sequence of a huCC49 light chain (SEQ ID NO: 9) and a corresponding nucleotide sequence (SEQ ID NO: 10) of the same light chain; --

Please replace the paragraph beginning at page 6, line 6, with the following rewritten paragraph:

-- Figs. 6A and 6B show, respectively, an amino acid sequence of an intact C5E10 heavy chain (SEQ ID NO: 11) and an amino acid sequence of a derived domain deleted C5E10 construct (SEQ ID NO: 12) wherein the C_H2 domain has been deleted; --

Please replace the paragraph beginning at page 6, line 9, with the following rewritten paragraph:

-- Figs. 7A and 7B show, respectively, a nucleotide sequence of an intact C5E10 heavy chain (SEQ ID NO: 13) and a nucleotide sequence of a derived domain deleted C5E10 construct (SEQ ID NO: 14) wherein the C_H2 domain has been deleted; --

Please replace the paragraph beginning at page 6, line 12, with the following rewritten paragraph:

-- Figs. 8A and 8B show, respectively, a nucleotide sequence of a C5E10 light chain (SEQ ID NO: 15) and the corresponding amino acid sequence (SEQ ID NO: 16) of the same light chain; --

Please replace the paragraph beginning at page 25, line 14, with the following rewritten paragraph:

-- It will be noted that the foregoing exemplary constructs were engineered to fuse the C_H3 domain directly to the hinge region of the respective modified antibodies. In other constructs it may be desirable to provide a peptide spacer between the hinge region and the modified C_H2 and/or C_H3 domains. For example, compatible constructs could be expressed wherein the C_H2 domain has been deleted and the remaining C_H3 domain (modified or unmodified) is joined to the hinge region with a 5 – 20 amino acid spacer. Such a spacer may be added, for instance, to ensure that the regulatory elements of the constant domain remain free and accessible or that the hinge region remains flexible. However, it should be noted that amino acid spacers may, in some cases, prove to be immunogenic or inhibit the desired dimerization of the monomeric subunits. For example, a domain deleted CC49 construct having a short amino acid spacer GGSSGGGGSG (~~Seq. ID No. 1~~) (SEQ ID NO: 17) substituted for the C_H2 domain (CC49.ΔC_H2 [gly/ser]) is used as a control in the examples because it does not assemble spontaneously into a dimeric form. Accordingly, any spacer compatible with the instant invention will be relatively non-immunogenic and not inhibit the non-covalent association of the modified antibodies. --

Please replace the paragraph beginning at page 49, line 23, with the following rewritten paragraph:

-- Following sequence confirmation of the immunoglobulin coding regions, this expression construct was transfected into CHO DG44 cells and selected for G418 resistance (conferred by a vector encoded neomycin phosphotransferase gene). Resistant cell isolates

were then assayed for HuCC49 C2B8. Δ C_H2 immunoglobulin expression. The nucleotide sequences encoding the light and heavy chains of C2B8. Δ C_H2 immunoglobulin in the resulting construct is are shown in Figs. 4–3 2B and 3A (SEQ ID NOs: 4 and 5). - -

Please replace the paragraph beginning at page 50, line 28, with the following rewritten paragraph:

- - Following sequence confirmation of the immunoglobulin coding regions, this expression construct was transfected into CHO DG44 cells and selected for G418 resistance (conferred by a vector encoded neomycin phosphotransferase gene). Resistant cell isolates were then assayed for HuCC49. Δ C_H2 immunoglobulin expression. The nucleotide sequences for the HuCC49. Δ C_H2 light and heavy chains is are shown in Figs. 4B and 5B (SEQ ID NOs: 8 and 10). - -